IRLAB Therapeutics AB (OSTO:IRLAB A) Effective Interest Rate on Debt % : 35.09% (As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. IRLAB Therapeutics AB's annualized positive value of Interest Expense for the quarter that ended in Mar. 2025 was kr22.26 Mil. IRLAB Therapeutics AB's average total debt for the quarter that ended in Mar. 2025 was kr63.44 Mil. Therefore, IRLAB Therapeutics AB's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2025 was 35.09%.

IRLAB Therapeutics AB Effective Interest Rate on Debt % Historical Data

The historical data trend for IRLAB Therapeutics AB's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRLAB Therapeutics AB Effective Interest Rate on Debt % Chart

IRLAB Therapeutics AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

5.22

7.77

5.62

1.26

23.81

IRLAB Therapeutics AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Effective Interest Rate on Debt %	Get a 7-Day Free Trial															30.42	23.91	20.35	19.64	35.09

Competitive Comparison of IRLAB Therapeutics AB's Effective Interest Rate on Debt %

For the Biotechnology subindustry, IRLAB Therapeutics AB's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IRLAB Therapeutics AB's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where IRLAB Therapeutics AB's Effective Interest Rate on Debt % falls into.

Save Embed

;

Save Embed

;

IRLAB Therapeutics AB Effective Interest Rate on Debt % Calculation

IRLAB Therapeutics AB's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2024 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Dec. 2023 )	+	Total Debt (A: Dec. 2024 ))	/ count )
=	-1 * -10.477	/	( (27.566	+	60.421)	/ 2 )
=	-1 * -10.477	/	43.9935
=	23.81 %

where

	Total Debt (A: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	24.626	+	2.94
=	27.566

	Total Debt (A: Dec. 2024 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	3.536	+	56.885
=	60.421

IRLAB Therapeutics AB's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2025 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Dec. 2024 )	+	Total Debt (Q: Mar. 2025 ))	/ count )
=	-1 * -22.264	/	( (60.421	+	66.462)	/ 2 )
=	-1 * -22.264	/	63.4415
=	35.09 %

where

	Total Debt (Q: Dec. 2024 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	3.536	+	56.885
=	60.421

	Total Debt (Q: Mar. 2025 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	2.674	+	63.788
=	66.462

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2025) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

IRLAB Therapeutics AB (OSTO:IRLAB A) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

IRLAB Therapeutics AB Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

IRLAB Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Arvid Wallgren Backe 20, Goteborg, SWE, 413 46

Website

https://www.irlab.se

IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB Headlines

No Headlines